Shawn Tomasello
CIK 1617239 · Chief Commercial Officer · last filed 2026-06-18
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
KITE price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
995 EAST ARQUES AVENUE
SUNNYVALE, CA 94085
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| FDMT | Director | — | $11.35 | — | $0 | 6 | 2026-06-18 |
| CABA | Director | 22,725 | $1.36 | $30.9K | $50.3K | 6 | 2026-06-10 |
| Kalaris Therapeutics, Inc. (ALVR) Delisted | Director | 3,043 | $9.81 | $29.9K | $0 | 4 | 2024-06-07 |
| Gamida Cell Ltd. (GMDA) Delisted | Director | 241,977 | $0.03 | $7.9K | $15.0K | 7 | 2024-02-02 |
| TCR2 THERAPEUTICS INC. (TCRR) Delisted | Director | — | $1.48 | — | $0 | 4 | 2023-06-01 |
| URGN | Director | — | $34.18 | — | $0 | 3 | 2021-06-09 |
| Principia Biopharma Inc. (PRNB) Delisted | Director | — | — | — | $0 | 4 | 2020-09-28 |
| ABEO | Director | 1,438 | $4.41 | $6.3K | $0 | 1 | 2020-05-22 |
| Diplomat Pharmacy, Inc. (DPLO) Delisted | Director | 33,259 | — | — | -$51.1K | 8 | 2020-02-10 |
| Kite Pharma, Inc. (KITE) Delisted | Chief Commercial Officer | 61,068 | — | — | -$1.00M | 4 | 2017-09-27 |
Recent Filings · Page 5 of 6
52 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-10-05 | — | Mixed | −61,068 | -$2.90M | |
| 2017-09-27 | Kite Pharma, Inc. (KITE) Delisted | Mixed | +297 | -$755.1K | EDGAR |
| 2017-06-05 | Diplomat Pharmacy, Inc. (DPLO) Delisted | Grant (A) | +4,722 | $0 | EDGAR |
| 2016-12-27 | Kite Pharma, Inc. (KITE) Delisted | Grant (A) | +10,600 | $0 | EDGAR |
| 2016-12-22 | Kite Pharma, Inc. (KITE) Delisted | Sell (S) | −4,901 | -$249.3K | EDGAR |
| 2016-06-02 | Diplomat Pharmacy, Inc. (DPLO) Delisted | Grant (A) | +1,483 | $0 | EDGAR |
| 2015-12-21 | Kite Pharma, Inc. (KITE) Delisted | Grant (A) | +44,000 | $0 | EDGAR |
| 2015-10-09 | Diplomat Pharmacy, Inc. (DPLO) Delisted | Grant (A) | +2,957 | $0 | EDGAR |
| 2015-05-28 | — | Mixed | −57,504 | -$15.02M | |
| 2015-02-27 | — | Disp (D) | −5,390 | -$745.8K |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.